Table 4 Treatment options in different groups
From: Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Type I-IS N = 61 | aType II IS N = 6 | Type III IS N = 8 | bMS-DMD N = 10 | |||
|---|---|---|---|---|---|---|
AZT N = 19 | MMF N = 12 | RTX N = 30 | ||||
Therapy choice, n (%) | ||||||
First line | 15 (78.9) | 6 (50) | 19 (63.3) | 5 (83.3) (3 CYC, 1 MTX, 1 MiTX) | 5 (62.5) (3 CS, 2 IVIG) | 10 (100) (6 IFN, 1 TFN, 1 GA, 2 NTZ) |
Second line | 3 (15.8) | 5 (41.7) | 5 (16.6) | 1 (16.6) (1 MTX) | 3 (37.5) (3 CS) | – |
Other lines | 1 (5.3) | 1 (8.3) | 6 (29.4) | – | – | |
Patients discontinuing treatment, n (%) | 9 (47.4) | 7 (58.3) | 3 (10) | 6 (100) | 5 (55.6) | 7 (70) |
Causes for discontinuing treatment, n (%) | ||||||
General intolerance | 2 (22.2) | 1 (14.3) | 1 (33.3) | – | – | 1 (14.3) |
Biological intolerance | 2 (22.2) | – | – | 1 (16.7) | – | – |
Physician decision | 2 (22.2) | 2 (28.6) | 1 (33.3) | 3 (50) | 4 (80) | 1 (14.3) |
Patient decision | 1 (11.1) | – | – | – | – | – |
Treatment failure | 2 (22.2) | 4 (57.1) | 1 (33.3) | 2 (33.3) | 1 (20) | 4 (57.1) |
Pregnancy desire | – | – | – | – | – | 1 (14.3) |